Amgen Inc. (AMGN) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: The setup into Q2 2026 is constructive but not stretched — consensus is a moderate bar with the six growth drivers (Repatha, EVENITY, TEZSPIRE, rare disease, innovative oncology, biosimilars) expected to continue their strong trajectory, while the primary swing factor is the pace of denosumab biosimilar erosion and whether UPLIZNA and IMDELLTRA can sustain their outsized beats.

Heading into Q2 2026, Amgen's setup is that of a quality compounder with a manageable bar: consensus expects total revenue of ~$9.43B (up ~3% YoY) and non-GAAP EPS of ~$5.58, both achievable given the momentum in the six growth drivers that collectively grew 24% YoY in Q1 and now represent ~70% of product sales. Management's tone on the Q1 call was unambiguously confident — raising full-year revenue guidance to $37.1–38.5B and non-GAAP EPS to $21.70–23.10, framing 2026 as a "springboard year" — and there has been no subsequent guidance revision, suggesting the raised bar is the right baseline. Estimate revisions since the Q1 print have been modestly positive, with Q2 consensus revenue ticking up ~$23M and EPS up ~$29M from the post-earnings baseline, indicating the Street is incrementally more constructive but not aggressively chasing the beat. The stock has rallied ~9% since the April 30 earnings date (vs. IBB +11%, SPY +6%), suggesting AMGN has broadly kept pace with biotech but has not priced in a material upside surprise; the multiple remains in-line with large-cap biotech peers, leaving room for a positive reaction if growth drivers outperform. The single biggest wildcard is the July 31 cybersecurity 8-K disclosing data exfiltration from cloud environments — while management stated it is not expected to materially impact financials, the investigation is ongoing and any new disclosures on the Q2 call could weigh on sentiment regardless of the underlying operational beat.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus is a moderate, beatable bar — the six growth drivers have consistently outpaced Street estimates, and UPLIZNA and IMDELLTRA are the biggest upside swing factors given their recent beat cadence; denosumab erosion is the primary downside risk if biosimilar competition accelerates faster than modeled.

Table 1 — Q2 2026 Current Quarter Snapshot (All Key KPIs)

Source: Visible Alpha consensus and actuals data. Q2 2026 consensus as of August 3, 2026. YoY change calculated vs. Q2 2025 actual. Guidance mid-point used for Consensus vs. Guidance calculation. TEZSPIRE Q2 2026 consensus of $485M reflects a notable step-up vs. Q1 actual of $343M, partly due to Q1 channel inventory burn; the Street is modeling a strong recovery. Note: Q2 2025 EPS actual shown is the VA consensus figure ($6.02) as the reported figure; Q1 2026 actual EPS of $5.15 reflects the reported non-GAAP diluted EPS.

Table 2 — Beat/Miss History: Top 2 KPIs (Last 8 Quarters)

Top 2 KPIs: Total Revenue and Non-GAAP Diluted EPS (the two metrics most frequently questioned by analysts and most directly tied to guidance).

Pattern: AMGN has beaten revenue consensus in 7 of the last 8 quarters and beaten non-GAAP EPS in 7 of 8, with EPS beats averaging ~9% over the period — a strong and consistent pattern that reflects conservative guidance-setting and execution discipline; the one EPS miss (Q2 2024, −0.5%) was marginal and driven by a one-time tax item. Source: Visible Alpha consensus and actuals data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance was raised on the Q1 2026 call (April 30) and has not been revised since — no 8-K, conference, or investor day has changed the financial outlook, though the July 31 cybersecurity disclosure is a new non-financial overhang that management will need to address on the Q2 call.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have moved modestly higher since the Q1 print — Q2 revenue consensus is up ~$23M and EPS up ~$29M from the post-earnings baseline — tracking in-line with raised guidance and suggesting the Street is not aggressively front-running a beat; the gap between consensus and guidance midpoints is narrow, leaving the bar achievable but not easy.

Source: Visible Alpha consensus and actuals data. Post-Q1 baseline uses consensus as of May 5, 2026 (5 trading days after April 30 earnings). Estimates have been remarkably stable since the Q1 print, with revisions of less than 1% across all key metrics — the Street is essentially holding its position and waiting for the Q2 print to confirm the trajectory. FY 2027 estimates are also flat, suggesting no incremental MariTide optionality has been priced in yet.

5. Stock Performance

Key Takeaway: AMGN has underperformed IBB (+11%) since the Q1 earnings date but outperformed the S&P 500 (+6%), with the stock's +9% gain driven primarily by multiple expansion and improving sentiment on the growth driver trajectory rather than estimate revisions (which have been flat); the post-earnings selloff in early May reversed by mid-June as the market re-rated the quality compounder narrative.

Since the Q1 2026 earnings date (April 30, 2026), AMGN closed at $346.25 on earnings day and has risen to $378.87 as of August 4, 2026 — a gain of +$32.62 / +9.4%. The stock initially sold off sharply to ~$323 in early May (the beat was largely anticipated per the after-hours reaction), then recovered steadily through June and July, reaching a high of ~$393 on July 28 before pulling back slightly following the July 31 cybersecurity 8-K disclosure. IBB (iShares Biotechnology ETF) is the appropriate sector benchmark given AMGN's large-cap biotech classification. Material events marked on the chart include the post-earnings selloff (May 1), the IMDELLTRA European Commission approval (July 2), and the cybersecurity 8-K (July 31). Source: Stock Price Data (Yahoo Finance).

AMGN vs. IBB (Biotech ETF) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings Date (April 30, 2026). Source: Yahoo Finance.

6. Material News & Developments

Key Takeaway: The most important development since Q1 earnings is the July 31 cybersecurity 8-K disclosing data exfiltration from cloud environments — while management stated it is not expected to materially impact financials, the ongoing investigation and potential patient data exposure create headline risk and will dominate Q&A on the Q2 call; operationally, the IMDELLTRA EU approval and AZN's TEZSPIRE commentary are the most constructive read-throughs.

• July 31, 2026 — Cybersecurity Incident 8-K (Material): Amgen disclosed unauthorized access to cloud-hosted data, with proprietary data and patient protected health information exfiltrated. Determined material on July 29. Company states no impact to products, manufacturing, or financial reporting systems. Investigation ongoing. Implication: Will be the dominant Q2 call topic; any new disclosures on scope or remediation cost could weigh on sentiment regardless of the operational beat.
• July 2, 2026 — IMDELLTRA European Commission Approval (Positive): EC approved tarlatamab for extensive-stage SCLC, expanding the global commercial opportunity. Management had guided for multiple ex-U.S. launches in 2026. Implication: Adds incremental revenue upside to Q2 and H2 2026 international sales; physician community described as highly excited about frontline/maintenance settings following ASCO 2026.
• June 2026 — ASCO 2026 Data Presentations (Positive): IMDELLTRA DeLLphi-303 Phase Ib data in first-line maintenance SCLC showed encouraging median OS of 25.3 months. Physician community described as highly excited about both frontline and maintenance settings. Implication: Reinforces IMDELLTRA's standard-of-care positioning and supports the ongoing Phase III DeLLphi-305 and DeLLphi-306 studies.
• May 2026 — Puerto Rico Investment Expansion (Strategic): Post-Q1 earnings, Amgen announced an additional ~$300M investment in Puerto Rico (on top of ~$650M previously announced), bringing total commitment to ~$1B. Implication: Reinforces strategic importance of the Juncos biologics facility and signals confidence in the Puerto Rico manufacturing base amid the ongoing IRS tax dispute.
• April 2026 — IRS Draft NOPA for 2016–2018 (Ongoing Overhang): IRS asserted significant adjustments related to profit allocation between U.S. and Puerto Rico. Amgen disputes the methodology and believes reserves are appropriate. 2010–2015 Tax Court decision expected no earlier than H2 2026. Implication: Headline risk remains; management has provided detailed offsets (~$2B in unwarranted penalties, ~$2B in calculation errors, ~$3.1B in prior repatriation taxes, ~$1.9B in cash deposits) suggesting actual cash exposure is materially lower than headline figures.
• April 2026 — FDA Proposed TAVNEOS Withdrawal (Negative Overhang): FDA formally proposed to withdraw TAVNEOS approval citing data manipulation concerns from original sponsor ChemoCentryx and new post-marketing safety signals (serious DILI, vanishing bile duct syndrome). TAVNEOS remains on market pending resolution. Q1 2026 sales were $119M (+32% YoY). Implication: If withdrawal proceeds, ~$500M annualized revenue at risk; Amgen is contesting vigorously. Watch for any FDA update on the Q2 call.
• May 2026 — AMG 193 Development Discontinued (Pipeline Pruning): Amgen discontinued development of its MTA-cooperative PRMT5 inhibitor following a comprehensive review. Implication: Reflects AI-driven R&D prioritization discipline; frees resources for higher-conviction assets. Minimal financial impact.
• May 2026 — Subcutaneous Blinatumomab Enrollment Pause (Watch): Enrollment in some subcutaneous blinatumomab studies paused due to a handful of inflammatory reactions. Management expected to reopen studies shortly after FDA dialogue. Implication: Monitor for update on enrollment resumption; IV BLINCYTO franchise ($415M in Q1, +12% YoY) is unaffected.
• Ongoing — Olpasiran OCEAN(a) Outcomes Study Timeline Extended (Watch): Completion date pushed out due to lower-than-expected endpoint accrual rate. Management attributed to better background care and potentially high drug efficacy reducing aggregate event rates. New OCEAN(a)-CCTA sub-study initiated. Implication: Delays the potential commercial catalyst but does not change conviction in the asset; Lp(a) awareness rising with updated ACC/AHA guidelines.
• No Analyst Rating Changes Identified: No upgrades or downgrades were found in the dataset for AMGN in the period since Q1 2026 earnings.

7. Peer Commentaries — Q2 2026 Read-Through Analysis

Key Takeaway: Peer commentary from AZN (Q2 2026 earnings), REGN (Q2 2026 earnings), LLY (ADA Investor Event, June 2026), and NVO (Q1 2026 earnings) provides broadly constructive read-throughs for AMGN's Q2 — TEZSPIRE's 45% YoY growth as reported by AZN is the single most important data point, directly validating AMGN's consensus estimate of $485M; the obesity/GLP-1 competitive landscape commentary from LLY and NVO is relevant context for MariTide positioning but does not change the near-term financial setup.

AstraZeneca (AZN) — Q2 2026 Earnings Call (July 27, 2026)

Read-Through Relevance: HIGH — AZN is AMGN's co-promotion partner for TEZSPIRE (tezepelumab) and reports its share of TEZSPIRE sales, providing a direct data point on the drug's Q2 2026 performance.

• TEZSPIRE grew 45% YoY to $390M in Q2 2026 (AZN's share). This is a direct and highly material read-through for AMGN's Q2 TEZSPIRE revenue. AZN reported strong performance in the U.S. and Europe, supplemented by uptake in emerging markets. AMGN's Q2 2026 consensus for TEZSPIRE is $485M — the AZN data point strongly validates this estimate and suggests potential for an upside surprise given the 45% growth rate vs. the ~42% YoY implied by consensus.
• AZN confirmed Phase 3 discussions with Amgen for inhaled TSLP (formerly AZD8630) following a positive Phase 2 readout. This is a pipeline positive for AMGN's TSLP franchise, extending the mechanism beyond TEZSPIRE into inhaled delivery.
• Respiratory & Immunology total revenue grew 11% in H1 2026, with Fasenra (IL-5) growing 13% and Breztri (COPD) growing 20%. The strong respiratory market backdrop is constructive for TEZSPIRE's continued penetration in asthma, CRS-NP, and COPD.
• AZN's oral GLP-1 (Olecko) Phase 3 program initiated, with Phase 2b data showing up to 11.8% weight loss at 36 weeks. AZN is also developing a fixed-dose combination of its oral PCSK9 with a GLP-1. This is relevant context for the broader obesity/cardiometabolic competitive landscape that MariTide will enter, but does not change AMGN's near-term setup.

Regeneron (REGN) — Q2 2026 Earnings Call (July 30, 2026)

Read-Through Relevance: MODERATE — REGN's Q2 2026 results are relevant for the inflammation/immunology market backdrop, the gMG competitive dynamics (Sondieren vs. UPLIZNA), and the biosimilar competition environment.

• Dupixent global net sales reached $6B in Q2 2026 (+38% YoY constant currency), with U.S. sales of $4.6B (+42% YoY). Demand across all nine approved indications remained robust, including COPD, CSU, bullous pemphigoid, and allergic fungal sinusitis. Read-through for AMGN: The strong inflammation/immunology market backdrop is constructive for UPLIZNA's continued growth in gMG, IgG4-RD, and NMOSD. Dupixent's dominance in atopic dermatitis and asthma does not directly compete with UPLIZNA's CD19 B-cell depletion mechanism.
• REGN's Sondieren (cemdisiran, C5 siRNA) FDA target action date is November 2026 for gMG. If approved, Sondieren would be the first siRNA for gMG with quarterly subcutaneous dosing. REGN characterized it as "highly differentiated" from C5 antibodies and fcrn treatments. Read-through for AMGN: This is the most direct competitive threat to UPLIZNA in gMG. However, AMGN management has previously characterized UPLIZNA's CD19 B-cell depletion mechanism as distinct from complement inhibition (C5), and noted UPLIZNA's twice-yearly dosing and durable efficacy as differentiators. The November FDA decision date means this competitive dynamic will not materially impact Q2 2026 results but is a key watch item for H2 2026 and 2027 guidance.
• REGN reported strong Q2 2026 overall performance: total revenues +17% YoY, non-GAAP EPS +11% YoY. Dupixent, Eylea HD, and Libtayo all set new all-time quarterly highs. Read-through for AMGN: The strong large-cap biotech earnings environment is broadly constructive for AMGN's Q2 setup.
• Eylea biosimilar competition accelerating in H2 2026: REGN guided for sequential demand declines in Eylea of low-to-mid teens in Q3 and Q4 due to multiple Aflibercept 2mg biosimilar launches. Read-through for AMGN: AMGN's PAVBLU (biosimilar Eylea) delivered $280M in Q1 2026 and is a key biosimilar growth driver. Accelerating Eylea biosimilar competition from multiple entrants could pressure PAVBLU's pricing and market share in H2 2026 — a modest headwind to watch.
• REGN advancing obesity portfolio (Hansoh GLP-1 dual agonist + Praluent combination): Phase 3 studies for the dual GLP-1/GIP agonist to initiate later in 2026. REGN is positioning the Praluent + GLP-1 combination as differentiated by also lowering LDL-C 50–60%. Read-through for AMGN: Reinforces the competitive intensity in the obesity/cardiometabolic space that MariTide will enter; the PCSK9 + GLP-1 combination concept is also relevant context for Repatha's positioning in the primary prevention market.

Eli Lilly (LLY) — ADA Cardiometabolic Health Portfolio Investor Event (June 6, 2026)

Read-Through Relevance: MODERATE — LLY's ADA investor event is directly relevant to MariTide's competitive positioning and the broader obesity market dynamics that will shape AMGN's long-term narrative, though it does not affect Q2 2026 financials.

• LLY introduced AuraLynn Tide (its amylin receptor agonist, a non-incretin obesity candidate) with Phase 2 data showing 12.4% weight loss at the 3mg dose ("placebo-like tolerability, no titration needed") and 16.4% at a higher dose with no plateau. LLY has five Phase 3 studies ongoing and described it as the "most efficacious and most tolerable molecule to date" in the amylin class. Read-through for AMGN: AuraLynn Tide is a direct competitor to MariTide in the non-incretin obesity space. LLY's amylin agonist is weekly (vs. MariTide's monthly/quarterly), but LLY's Phase 3 program is already underway. This increases the competitive pressure on MariTide's differentiation narrative — AMGN will need to demonstrate superior or comparable efficacy with a clear convenience advantage (4–6 injections/year vs. 52 for weekly agents).
• LLY's patient switching data is directly relevant to AMGN's SWITCH study rationale: LLY showed that switching from injectable Wegovy to Orforglipron maintained 95% of weight loss, and switching from max-dose Zepbound to Orforglipron preserved ~76% of weight loss. Read-through for AMGN: Validates the switch patient opportunity that AMGN is targeting with MariTide's SWITCH study (switching from weekly semaglutide/tirzepatide to MariTide every 8 or 12 weeks). The data suggests patients can switch without major weight regain, supporting the commercial rationale for MariTide's convenience-driven positioning.
• LLY confirmed Orforglipron (oral GLP-1) NDA submission for type 2 diabetes in Q2 2026, with obesity submission on track for H2 2026. Retatrutide (triple agonist) submission on track for H2 2026. Read-through for AMGN: The obesity market is rapidly expanding with multiple new entrants. LLY's ambition to launch 4–5 obesity medicines by end of decade underscores the competitive intensity MariTide will face, but also validates the massive market opportunity.
• LLY emphasized the market is still in "low single digits" penetration of the 100M+ U.S. patients who could benefit from obesity medicines. Read-through for AMGN: Constructive for MariTide's long-term opportunity; the market is large enough for multiple winners, and AMGN's monthly/quarterly dosing profile targets a distinct patient preference segment.

Novo Nordisk (NVO) — Q1 2026 Earnings Call (May 6, 2026)

Read-Through Relevance: MODERATE — NVO's Q1 2026 results and commentary are relevant to the GLP-1 market dynamics, pricing trends, and competitive landscape that will shape MariTide's commercial environment.

• NVO's Wegovy pill (oral semaglutide) had a "record-breaking start" with 1M+ users in ~16 weeks, with ~80% of users being GLP-1 treatment-naive. The Wegovy franchise holds ~65% new-to-brand prescription market share in branded anti-obesity medications. Read-through for AMGN: The oral GLP-1 category is expanding rapidly and attracting new patients rather than cannibalizing injectables — constructive for the overall market size but also signals that the convenience bar for injectable therapies like MariTide is rising.
• NVO guided FY 2026 adjusted sales growth of −4% to −12% at CER, citing intensifying competition, reduced Medicaid obesity coverage, and lower realized prices (Ozempic U.S. price erosion of −10% to −15%). Read-through for AMGN: The pricing pressure in the GLP-1 market is a key watch item for MariTide's commercial strategy. AMGN management has noted GLP-1 pricing trends are "in line with expectations" and is preparing for both the insured/reimbursement market and the consumer segment.
• NVO advancing CagriSema (cagrilintide + semaglutide) with U.S. decision expected end of 2026, and zenagamtide (oral amylin) Phase 3 program (AMAZE) underway. UBT251 (triple agonist GLP-1/GIP/glucagon) showed 19.7% weight loss in Phase 2 obesity trial. Read-through for AMGN: The pipeline of next-generation obesity agents is expanding rapidly. MariTide's differentiation will need to be demonstrated in Phase 3 data (expected early 2027) to maintain investor confidence in the asset's commercial potential.
• NVO's international obesity care sales grew 44% YoY in Q1 2026, with NVO holding ~55% weekly injectable GLP-1 volume market share internationally. Read-through for AMGN: The international obesity market is growing rapidly, validating the global commercial opportunity for MariTide if Phase 3 data supports approval.

Peer Read-Through Summary Table

8. Insider Transaction Activity

Key Takeaway: No open-market buys or discretionary sells were identified in the period since Q1 2026 earnings — all transactions are routine compensation-related (Form 4 code F = tax withholding on vesting, code A = award grants, code S = one small discretionary sale by CCO Grygiel). The pattern is unremarkable and sends no directional signal.

Source: SEC Form 4 filings via Insider Transaction Data. Period covered: April 30, 2026 – August 3, 2026. Only open-market buys (code P) and sells (code S) plus 10b5-1 plan initiations are flagged as directional signals. All other transactions (code F = tax withholding, code A = award grant) are routine compensation events. The one open-market sale (Grygiel, May 4) is modest in size and not part of a 10b5-1 plan, but is not unusual for a CCO-level executive following a vesting event. No open-market buys were recorded in the period. No 10b5-1 plan initiations were identified. Overall: no notable insider signal.

— End of Report —

Disclosures: This document is prepared for informational purposes only. All consensus estimates sourced from Visible Alpha. Stock price data sourced from Yahoo Finance. Insider transaction data sourced from SEC Form 4 filings. Peer commentary sourced from earnings call transcripts and investor event transcripts. Prepared: August 3, 2026.